Login Register Cart 0
Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Biologics in Children with Allergic Diseases

Author(s): Amelia Licari, Sara Manti, Alessia Marseglia, Maria De Filippo, Elisabetta De Sando, Thomas Foiadelli and Gian Luigi Marseglia*

Volume 16, Issue 2, 2020

Page: [140 - 147] Pages: 8

DOI: 10.2174/1573396315666191029123822

Price: $65

Abstract

The prevalence of allergic diseases has been remarkably increased in the last decades. The global health burden of these conditions is substantial, since patients may experience disability, anxiety and emotional distress, social restrictions, and reduced quality of life and productivity, in particular, in the most severe cases. Recent advances in understanding the pathophysiology of allergic disorders have allowed identifying novel therapeutic strategies for the treatment of severe and uncontrolled allergic diseases. Although most studies have been performed in allergic asthma, biological drugs targeting other allergic diseases such as chronic spontaneous urticaria, atopic dermatitis, and food allergy are showing promising results. In this review, the most recent evidence on biologic therapies for allergic diseases, focusing on the pediatric age has been presented.

Keywords: Asthma, atopic dermatitis, biologics, children, chronic spontaneous urticaria, food allergy.

« Previous Next »
[1]
Sánchez-Borges M, Martin BL, Muraro AM, et al. The importance of allergic disease in public health: an iCAALL statement. World Allergy Organ J 2018; 11(1): 8.
[http://dx.doi.org/10.1186/s40413-018-0187-2] [PMID: 29743965]
[2]
Manka LA, Wechsler ME. New biologics for allergic diseases. Expert Rev Clin Immunol 2018; 14(4): 285-96.
[http://dx.doi.org/10.1080/1744666X.2018.1459188] [PMID: 29611440]
[3]
Licari A, Castagnoli R, Brambilla I, et al. Asthma Endotyping and Biomarkers in Childhood Asthma. Pediatr Allergy Immunol Pulmonol 2018; 31(2): 44-55.
[http://dx.doi.org/10.1089/ped.2018.0886] [PMID: 30069422]
[4]
Licari A, Brambilla I, Marseglia A, De Filippo M, Paganelli V, Marseglia GL. Difficult vs. severe asthma: definition and limits of asthma control in the pediatric population. Front Pediatr 2018; 6: 170.
[http://dx.doi.org/10.3389/fped.2018.00170] [PMID: 29971223]
[5]
Bush A. Pathophysiological mechanisms of asthma. Front Pediatr 2019; 7: 68.
[http://dx.doi.org/10.3389/fped.2019.00068] [PMID: 30941334]
[6]
Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs 2014; 16(6): 491-502.
[http://dx.doi.org/10.1007/s40272-014-0107-z] [PMID: 25404353]
[7]
Licari A, Marseglia G, Castagnoli R, Marseglia A, Ciprandi G. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov 2015; 10(9): 1033-42.
[http://dx.doi.org/10.1517/17460441.2015.1048220] [PMID: 25979110]
[8]
Licari A, Castagnoli R, Brambilla I, et al. New approaches for identifying and testing potential new anti-asthma agents. Expert Opin Drug Discov 2018; 13(1): 51-63.
[http://dx.doi.org/10.1080/17460441.2018.1396315] [PMID: 29077521]
[9]
Licari A, Castagnoli R, Panfili E, Marseglia A, Brambilla I, Marseglia GL. An update on anti-IgE therapy in pediatric respiratory diseases. Curr Respir Med Rev 2017; 13(1): 22-9.
[http://dx.doi.org/10.2174/1573398X13666170616110738] [PMID: 29290750]
[10]
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43(2): 343-73.
[http://dx.doi.org/10.1183/09031936.00202013] [PMID: 24337046]
[11]
Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol 2017; 139(5): 1431-44.
[http://dx.doi.org/10.1016/j.jaci.2017.03.002] [PMID: 28477722]
[12]
Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 2012; 97(7): 604-9.
[http://dx.doi.org/10.1136/archdischild-2011-301570] [PMID: 22685051]
[13]
Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364(11): 1005-15.
[http://dx.doi.org/10.1056/NEJMoa1009705] [PMID: 21410369]
[14]
Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136(6): 1476-85.
[http://dx.doi.org/10.1016/j.jaci.2015.09.008] [PMID: 26518090]
[15]
Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42(5): 1224-33.
[http://dx.doi.org/10.1183/09031936.00149812] [PMID: 23520319]
[16]
Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J 2015; 46(3): 856-9.
[http://dx.doi.org/10.1183/09031936.00008115] [PMID: 26022964]
[17]
Licari A, Castagnoli R, Denicolò C, et al. Omalizumab in children with severe allergic asthma: The italian real-life experience. Curr Respir Med Rev 2017; 13(1): 36-42.
[http://dx.doi.org/10.2174/1573398X13666170426094536] [PMID: 29213221]
[18]
Pitrez PM, de Souza RG, Roncada C, et al. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study. Pediatr Pulmonol 2017; 52(11): 1408-13.
[http://dx.doi.org/10.1002/ppul.23845] [PMID: 29027379]
[19]
Novelli F, Latorre M, Vergura L, et al. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther 2015; 31: 123-9.
[http://dx.doi.org/10.1016/j.pupt.2014.09.007] [PMID: 25281265]
[20]
Busse W, Haselkorn T, Rosén K, et al. Greater treatment benefit with omalizumab in children with increased asthma severity: Exploratory analyses from the inner-city anti-IgE therapy for Asthma (ICATA) Study. J Allergy Clin Immunol 2018; 141(2)(Suppl.): AB14.
[http://dx.doi.org/10.1016/j.jaci.2017.12.045]
[21]
Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract 2013; 1(2): 163-71.
[http://dx.doi.org/10.1016/j.jaip.2013.01.011] [PMID: 24565455]
[22]
Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187(8): 804-11.
[http://dx.doi.org/10.1164/rccm.201208-1414OC] [PMID: 23471469]
[23]
Bongiovanni A, Parisi GF, Scuderi MG, et al. Gastroesophageal reflux and respiratory diseases: does a real link exist? Minerva Pediatr 2019; 71(6): 515-23.
[http://dx.doi.org/10.23736/S0026-4946.19.05531-2] [PMID: 31129955]
[24]
Marseglia L, Manti S, D’Angelo G, et al. Gastroesophageal reflux and congenital gastrointestinal malformations. World J Gastroenterol 2015; 21(28): 8508-15.
[http://dx.doi.org/10.3748/wjg.v21.i28.8508] [PMID: 26229394]
[25]
Poddighe D, Brambilla I, Licari A, Marseglia GL. Pediatric rhinosinusitis and asthma. Respir Med 2018; 141: 94-9.
[http://dx.doi.org/10.1016/j.rmed.2018.06.016] [PMID: 30053979]
[26]
Marseglia GL, Pagella F, Licari A, et al. Acute isolated sphenoid sinusitis in children. Int J Pediatr Otorhinolaryngol 2006; 70(12): 2027-31.
[http://dx.doi.org/10.1016/j.ijporl.2006.07.011] [PMID: 16930730]
[27]
Licari A, Brambilla I, De Filippo M, Poddighe D, Castagnoli R, Marseglia GL. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med 2017; 11(11): 855-65.
[http://dx.doi.org/10.1080/17476348.2017.1381564] [PMID: 28918658]
[28]
Sesé L, Schneider M, Bourgoin M, et al. Asthma with multiple allergic comorbidities is associated with complete response to omalizumab. Clin Exp Allergy 2019; 49(5): 733-5.
[http://dx.doi.org/10.1111/cea.13373] [PMID: 30779241]
[29]
Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014; 134(3): 560-567.e4.
[http://dx.doi.org/10.1016/j.jaci.2014.02.007] [PMID: 24679845]
[30]
NUCALA (mepolizumab) EMA approval 2014. Available from: https://gskprocom/content/
[31]
Nucala (mepolizumab) for injection [prescribing information] Research Triangle Park, NC: GlaxoSmithKline. 2015.
[32]
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380(9842): 651-9.
[http://dx.doi.org/10.1016/S0140-6736(12)60988-X] [PMID: 22901886]
[33]
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371(13): 1198-207.
[http://dx.doi.org/10.1056/NEJMoa1403290] [PMID: 25199059]
[34]
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371(13): 1189-97.
[http://dx.doi.org/10.1056/NEJMoa1403291] [PMID: 25199060]
[35]
Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther 2016; 38(9): 2058-2070.e1.
[http://dx.doi.org/10.1016/j.clinthera.2016.07.010] [PMID: 27553751]
[36]
Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2019; 143(5): 1742-1751.e7.
[http://dx.doi.org/10.1016/j.jaci.2018.09.033] [PMID: 30359681]
[37]
Drick N, Seeliger B, Welte T, Fuge J, Suhling H. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. BMC Pulm Med 2018; 18(1): 119.
[http://dx.doi.org/10.1186/s12890-018-0689-2] [PMID: 30021546]
[38]
Haldar P. Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. Biologics 2017; 11: 81-95.
[http://dx.doi.org/10.2147/BTT.S93954] [PMID: 28721009]
[39]
Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176(11): 1062-71.
[http://dx.doi.org/10.1164/rccm.200701-085OC] [PMID: 17872493]
[40]
Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 2017.
[http://dx.doi.org/10.1002/14651858.CD010834.pub3]
[41]
CINQAIR (reslizumab) prescribing information 2016. Available from: https://wwwaccessdatafdagov/drugsatfda_docs/label/2016/761033lblpdf
[42]
Cooper K, Frampton G, Harris P, Rose M, Chorozoglou M, Pickett K. Reslizumab for Treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: An evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics 2018; 36(5): 545-53.
[http://dx.doi.org/10.1007/s40273-017-0608-z] [PMID: 29582406]
[43]
Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 2016; 150(4): 799-810.
[http://dx.doi.org/10.1016/j.chest.2016.03.018] [PMID: 27018175]
[44]
Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016; 150(4): 789-98.
[http://dx.doi.org/10.1016/j.chest.2016.03.032] [PMID: 27056586]
[45]
Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3(5): 355-66.
[http://dx.doi.org/10.1016/S2213-2600(15)00042-9] [PMID: 25736990]
[46]
Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med 2018; 197(1): 38-46.
[http://dx.doi.org/10.1164/rccm.201707-1323OC] [PMID: 28915080]
[47]
Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract 2017; 5(6): 1572-1581.e3.
[http://dx.doi.org/10.1016/j.jaip.2017.08.024] [PMID: 29122156]
[48]
Pediatric Postmarketing Pharmacovigilance Review 2014. Available from: https://wwwfdagov/media/114068/download
[49]
Sridhar S, Liu H, Pham TH, Damera G, Newbold P. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res 2019; 20(1): 14.
[http://dx.doi.org/10.1186/s12931-018-0968-8] [PMID: 30658649]
[50]
AstraZeneca Fasenra (benralizumab) prescribing information November 2017. Available from: https://wwwazpicentralcom/fasenra/fasenra_pipdf#page=1
[51]
AstraZeneca Fasenra (benralizumb) Summary of product characteristics 2018. Available from: https://eceuropaeu/health/documents/communityregis-ter/2018/20180108139598/anx_139598_enpdf
[52]
Matera MG, Calzetta L, Rinaldi B, Cazzola M. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opin Drug Metab Toxicol 2017; 13(9): 1007-13.
[http://dx.doi.org/10.1080/17425255.2017.1359253] [PMID: 28737051]
[53]
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388(10056): 2115-27.
[http://dx.doi.org/10.1016/S0140-6736(16)31324-1] [PMID: 27609408]
[54]
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388(10056): 2128-41.
[http://dx.doi.org/10.1016/S0140-6736(16)31322-8] [PMID: 27609406]
[55]
Chia YL, Yan L, Yu B, et al. Relationship between benralizumab exposure and efficacy for patients with severe eosinophilic asthma. Clin Pharmacol Ther 2019; 106(2): 383-90.
[http://dx.doi.org/10.1002/cpt.1371] [PMID: 30661249]
[56]
Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 2019; 7(1): 46-59.
[http://dx.doi.org/10.1016/S2213-2600(18)30406-5] [PMID: 30416083]
[57]
Benralizumab (Fasenra) for Severe Eosinophilic Asthma JAMA 2018; 319(14): 1501-2.
[http://dx.doi.org/10.1001/jama.2018.3609] [PMID: 29634828]
[58]
A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI) ClinicalTrialsgov Identifier: NCT02808819 2014. Available from: https://clinicaltrialsgov/ct2/show/NCT02808819
[59]
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73(7): 1393-414.
[http://dx.doi.org/10.1111/all.13397] [PMID: 29336054]
[60]
Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017; 72(4): 519-33.
[http://dx.doi.org/10.1111/all.13083] [PMID: 27861988]
[61]
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015; 135(1): 67-75.
[http://dx.doi.org/10.1038/jid.2014.306] [PMID: 25046337]
[62]
Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368(10): 924-35.
[http://dx.doi.org/10.1056/NEJMoa1215372] [PMID: 23432142]
[63]
Sussman G, Hébert J, Barron C, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2014; 112(2): 170-4.
[http://dx.doi.org/10.1016/j.anai.2013.12.005] [PMID: 24468258]
[64]
Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014; 73(1): 57-62.
[http://dx.doi.org/10.1016/j.jdermsci.2013.08.011] [PMID: 24060603]
[65]
Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol 2018; 141(2): 638-49.
[http://dx.doi.org/10.1016/j.jaci.2017.06.032] [PMID: 28751232]
[66]
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016; 137(6): 1742-1750.e4.
[http://dx.doi.org/10.1016/j.jaci.2015.12.1342] [PMID: 27040372]
[67]
Ferrer M, Boccon-Gibod I, Gonçalo M, et al. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria. Eur J Dermatol 2017; 27(5): 455-63.
[http://dx.doi.org/10.1684/ejd.2017.3085] [PMID: 29084635]
[68]
Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol 2019; 33(5): 918-24.
[http://dx.doi.org/10.1111/jdv.15350] [PMID: 30451325]
[69]
Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol 2016; 175(2): 404-6.
[http://dx.doi.org/10.1111/bjd.14540] [PMID: 26972689]
[70]
Deza G, Bertolín-Colilla M, Pujol RM, et al. Basophil FceRI expression inchronic spontaneous urticaria: a potential immunological predictor ofresponse to omalizumab therapy. Acta Derm Venereol 2017; 97(6): 698-704.
[http://dx.doi.org/10.2340/00015555-2654] [PMID: 28303277]
[71]
Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017; 139(3): 1059-1061.e1.
[http://dx.doi.org/10.1016/j.jaci.2016.07.047] [PMID: 27838346]
[72]
Asero R, Marzano AV, Ferrucci S, Cugno M. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU. J Allergy Clin Immunol Pract 2017; 5(6): 1740-2.
[http://dx.doi.org/10.1016/j.jaip.2017.07.009] [PMID: 28866106]
[73]
Vadasz Z, Tal Y, Rotem M, et al. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients. J Allergy Clin Immunol Pract 2017; 5(6): 1743-5.
[http://dx.doi.org/10.1016/j.jaip.2017.08.035] [PMID: 28988786]
[74]
Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014; 44(11): 1371-85.
[http://dx.doi.org/10.1111/cea.12400] [PMID: 25200415]
[75]
Dose-finding Study of QGE031 as add-on Therapy to Evalu-ate Efficacy and Safety in Patients With CSU ClinicalTrialsgov Identifier: NCT02477332 2014. Available from: https://clinicaltrialsgov/ct2/show/NCT02477332
[76]
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients ClinicalTrialsgov Identifier: NCT02649218 2014. Available from: https://clinicaltrialsgov/ct2/show/NCT02649218
[77]
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) ClinicalTrialsgov Identifier Available from: https://clinicaltrialsgov/ct2/show/NCT03437278
[78]
Scheerens H, Putnam W, Zheng Y, et al. Treatment with MEMP1972A, an anti-M1 prime monoclonal antibody, reducedserum IgE in healthy volunteers and patients with allergic rhinitis. Am J Respir Crit Care Med 2012; 185: A6791.
[79]
Gauvreau GM, Harris JM, Scheerens H, et al. Targeting membrane-expressed IgE B cell receptor with an an-tibody against theM1 prime epitope: a novel method of reduc-ing production of serum IgE. Sci Transl Med 2014; 6(243)243ra85
[80]
Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin Immunol 2016; 138(6): 1730-2.
[http://dx.doi.org/10.1016/j.jaci.2016.06.023] [PMID: 27567329]
[81]
Pennington LF, Tarchevskaya S, Brigger D, et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun 2016; 7: 11610.
[http://dx.doi.org/10.1038/ncomms11610] [PMID: 27194387]
[82]
Nyborg AC, Zacco A, Ettinger R, et al. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol 2016; 13(3): 391-400.
[http://dx.doi.org/10.1038/cmi.2015.19] [PMID: 25942513]
[83]
Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009; 124(6): 1251-8.e23.
[http://dx.doi.org/10.1016/j.jaci.2009.10.009] [PMID: 20004783]
[84]
Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2015; 73(2): 311-8.
[http://dx.doi.org/10.1016/j.cyto.2014.11.023] [PMID: 25542094]
[85]
Manti S, Chimenz R, Salpietro A, et al. Atopic dermatitis: expression of immunological imbalance. J Biol Regul Homeost Agents 2015; 29(2)(Suppl. 1): 13-7.
[PMID: 26634582]
[86]
Cuppari C, Manti S, Salpietro A, et al. HMGB1 levels in children with atopic eczema/dermatitis syndrome (AEDS). Pediatr Allergy Immunol 2016; 27(1): 99-102.
[http://dx.doi.org/10.1111/pai.12481] [PMID: 26388323]
[87]
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371(2): 130-9.
[http://dx.doi.org/10.1056/NEJMoa1314768] [PMID: 25006719]
[88]
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016; 375(24): 2335-48.
[http://dx.doi.org/10.1056/NEJMoa1610020] [PMID: 27690741]
[89]
Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014; 134(6): 1293-300.
[http://dx.doi.org/10.1016/j.jaci.2014.10.013] [PMID: 25482871]
[90]
Tsianakas A, Luger TA, Radin A. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol 2018; 178(2): 406-14.
[http://dx.doi.org/10.1111/bjd.15905] [PMID: 28845523]
[91]
Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387(10013): 40-52.
[http://dx.doi.org/10.1016/S0140-6736(15)00388-8] [PMID: 26454361]
[92]
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389(10086): 2287-303.
[http://dx.doi.org/10.1016/S0140-6736(17)31191-1] [PMID: 28478972]
[93]
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32(6): 850-78.
[http://dx.doi.org/10.1111/jdv.14888] [PMID: 29878606]
[94]
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥ 6 to 18 Years With Atopic Dermatitis (Eczema) ClinicalTrialsgov Identifier: NCT02 407756 Available from: https://clinicaltrialsgov/ct2/show/NCT02407756
[95]
Efficacy and Safety of Dupilumab in Patients ≥12 to 18 Years of Age, With Moderate-to-Severe Atopic Dermatitis Clinical Trialsgov Identifier: NCT03054428 Available from: https://clinicaltrialsgov/ct2/show/NCT03054428
[96]
Safety, Pharmacokinetics and Efficacy of Dupilumab in Pa-tients. 2014.
[97]
Study to Assess the Long-term Safety of Dupilumab Admin-istered in Participants 2014.
[98]
Dupilumab Phase 4 Study (DRS) ClinicalTrialsgov Identifier: NCT03411837 2014. Available from: https://clinicaltrialsgov/ct2/show/NCT03411837
[99]
Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol 2010; 126(6): 1105-18.
[http://dx.doi.org/10.1016/j.jaci.2010.10.008] [PMID: 21134568]
[100]
Osborne NJ, Koplin JJ, Martin PE, et al. Prevalence of challenge-proven IgE-mediated food allergy us-ing population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 2011; 127(3): 668-76.
[101]
Licari A, Manti S, Marseglia A, et al. Food Allergies: Current and Future Treatments. Medicina (Kaunas) 2019; 55(5)E120
[http://dx.doi.org/10.3390/medicina55050120] [PMID: 31052434]
[102]
Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348(11): 986-93.
[http://dx.doi.org/10.1056/NEJMoa022613] [PMID: 12637608]
[103]
Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge re-sponses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012; 130(5): 1123-9.
[104]
Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013; 132(6): 1368-74.
[http://dx.doi.org/10.1016/j.jaci.2013.09.046] [PMID: 24176117]
[105]
Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 2011; 127(6): 1622-4.
[http://dx.doi.org/10.1016/j.jaci.2011.04.009] [PMID: 21546071]
[106]
Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2018; 3(2): 85-94.
[http://dx.doi.org/10.1016/S2468-1253(17)30392-8] [PMID: 29242014]
[107]
Martorell-Calatayud C, Michavila-Gómez A, Martorell-Aragonés A, et al. Anti-IgE-assisted desensitization to egg and cow’s milk in patients refractory to conventional oral immunotherapy. Pediatr Allergy Immunol 2016; 27(5): 544-6.
[http://dx.doi.org/10.1111/pai.12567] [PMID: 27003835]
[108]
Bedoret D, Singh AK, Shaw V, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow’s milk allergy enabled with omalizumab. Mucosal Immunol 2012; 5(3): 267-76.
[http://dx.doi.org/10.1038/mi.2012.5] [PMID: 22318492]
[109]
Sampson HA. A phase II, randomized, double-blind, parallel group, place-bo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2007; 119: S117-23.
[110]
Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014; 10(1): 7.
[http://dx.doi.org/10.1186/1710-1492-10-7] [PMID: 24576338]

Rights & Permissions Print Cite
Article Metrics
13
© 2024 Bentham Science Publishers | Privacy Policy